The safety of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension: Protocol for a systemic review and network meta-analysis

BACKGROUND: Pulmonary arterial hypertension (PAH) is a progressive disease and ultimately leads to right heart failure. Endothelin receptor antagonists (ERAs) have been demonstrated to significantly improve prognosis in PAH. However, ERAs-induced side effects can result in poor patient tolerance. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Zhi-Chun, Zhang, Yi-Jing, Pan, Mang-Mang, Zhang, Chi, Liu, Xiao-Yan, Wei, An-Hua, Su, Ying-Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
3400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882387/
https://www.ncbi.nlm.nih.gov/pubmed/29538209
http://dx.doi.org/10.1097/MD.0000000000010122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882387/
https://www.ncbi.nlm.nih.gov/pubmed/29538209
http://dx.doi.org/10.1097/MD.0000000000010122

Ejemplares similares